Who Paid My Doc
BI 425809 Pivotal efficacy study 1
Research payments
$1,241,138
Through program year 2023, $1,241,138 in research payments was reported against BI 425809 Pivotal efficacy study 1, across 74 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim RCV GmbH & Co KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $576,855 | 29 |
| 2022 | Research | $576,682 | 36 |
| 2021 | Research | $87,601 | 9 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Tshekedi Dennis Mission Viejo, CA Named on 7 payments
- Shishuka Malhotra North Canton, OH Named on 7 payments
- James Knutson Kirkland, WA Named on 7 payments
- Eric Chavez San Diego, CA Named on 6 payments
- Diana Ghelber Granbury, TX Named on 6 payments
- Wakelin McNeel La Habra, CA Named on 5 payments
- Suresh Sureddi Plano, TX Named on 3 payments
- Francisco Ricart Miami, FL Named on 3 payments
- Nancy Navarro Gonzalez Miami, FL Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.